Guide contents
Open in calculatorCompound briefing
Selank is a synthetic heptapeptide analogue of the immunomodulatory peptide tuftsin, developed at the Russian Institute of Molecular Genetics. It is studied for anxiolytic, nootropic and immunomodulatory effects, with a notably non-sedating profile and no benzodiazepine-style dependency liability in research.
The research question
Selank is investigated for anxiety, stress response and cognition without framing sedation as the desired endpoint. GABAergic, enkephalin and neurotrophic mechanisms are proposed, but their relative contribution remains unsettled.
Mechanism & research themes
Modulates GABA and serotonin systems indirectly, upregulates BDNF expression, and influences enkephalin metabolism via inhibition of enkephalin-degrading enzymes. Also exerts immunomodulatory effects via interleukin balance.
Anxiolytic effect comparable to benzodiazepines in animal models without sedation
Upregulation of BDNF supporting neuroplasticity
Improved focus, working memory and stress resilience
No reported dependency, tolerance or withdrawal in research
Immunomodulatory effects relevant to viral and inflammatory research
Rapid onset, particularly via intranasal administration
These are research themes reported across the literature, not established benefits or indications.
Evidence assessment
Most clinical reports originate from a regional literature with limited independent replication. Comparisons with established anxiolytics require cautious interpretation.
What to look for
Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.
What not to assume
A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.
Protocol literature
Commonly referenced research protocols use 250–500mcg intranasally or subcutaneously 1–3× daily. Intranasal is the most common route. Cycles typically run 2–4 weeks of active use.
Reported persistence
Short plasma half-life (approximately 30 minutes), but functional CNS effects persist longer due to receptor-system modulation.
Calculator starting point
0.3 mg per reference dose
5 doses per week · 4-week cycle
2 mL default reconstitution volume
250–500 mcg SC or intranasal, short cycles.
Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.
Calculate SelankLaboratory handling
Reconstitution reference
Reconstitute a 5mg vial with 2–5mL bacteriostatic water (or sterile saline for intranasal use). Swirl gently.
Storage reference
Lyophilised: 2–8°C, stable 18–24 months. Reconstituted: 2–8°C, protect from light, use within 30 days.
Minimum documentation standard
- Record the lot identifier and review its matching analytical documentation.
- Use aseptic technique and record diluent, final volume and calculated concentration.
- Label preparation date, storage conditions and any light or freeze–thaw restrictions.
- Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Limitations & safety
Most clinical research originates from Russian-language literature; Western RCT data is limited.
Intranasal administration may cause transient irritation or taste changes.
Long-term safety beyond several months of continuous use is not well characterised.
Research use only
This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.
Continue reading